NDA 020702 · Upjohn
Lipitor
Atorvastatin Calcium · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Apr 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Dec 17, 1996
Approved uses
11
Original approval plus efficacy supplements
Registered trials
1,099
271 Phase 3, 75 recruiting
FAERS reports
248,656
160,978 serious, 18,815 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 15, 2024.
LIPITOR is indicated: • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. • As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and...
Mechanism: LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 2017 Supplement 67 · Efficacy LetterLabel
- Mar 2, 2007 Supplement 47 · Efficacy LabelLetter
- Sep 21, 2005 Supplement 42 · Efficacy LetterLabel
- Jul 30, 2004 Supplement 39 · Efficacy ReviewLetter
- Oct 18, 2002 Supplement 33 · Efficacy LabelLetter
- Apr 22, 2002 Supplement 29 · Efficacy LetterLabel
- Jun 8, 2001 Supplement 25 · Efficacy LabelReviewLetter
- Dec 2, 1999 Supplement 18 · Efficacy ReviewLetter
- Jul 10, 1998 Supplement 5 · Efficacy ReviewLetter
- Jul 10, 1998 Supplement 3 · Efficacy LetterReview
- Dec 17, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
4 products under this application
- LIPITOR · ATORVASTATIN CALCIUM EQ 80MG BASE · TABLET, ORAL · Prescription · TE AB
- LIPITOR · ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- LIPITOR · ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- LIPITOR · ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Atorvastatin" as an intervention, any sponsor and status, largest first.
- Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) TrialPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT06856772 · 42,000 participants (planned) · Start Feb 28, 2025 · Primary completion Mar 28, 2028
Drug: Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) · For: Cardiovascular Diseases (CVD); Drug Effect; Atherosclerosis Cardiovascular Disease
Sites: Hellerup, Denmark
- Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older AdultsPivotal-lookingRecruiting
Duke UniversityAcademic, hospital or other
NCT04262206 · 20,000 participants (planned) · Start Sep 1, 2020 · Primary completion Dec 31, 2026
Drug: Atorvastatin 40 Mg Oral Tablet; Placebo oral tablet · For: Cognitive Impairment, Mild; Dementia; Cardiovascular Diseases
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 106 sites in all
- ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01663402 · 18,924 participants · Start Oct 2012 · Primary completion Jan 23, 2018
Drug: Alirocumab; Placebo and 1 more · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,388 sites in all
- A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart DiseasePivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00134264 · 15,067 participants · Start Jul 2004 · Primary completion Jun 2007
Drug: torcetrapib/atorvastatin; atorvastatin · For: Coronary Disease; Diabetes Mellitus
Sites: Alabaster, Alabama; Birmingham, Alabama; Gilbert, Arizona · 221 sites in all
- Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets StudyPivotal-lookingCompleted
Korea University Guro HospitalAcademic, hospital or other
NCT03073863 · 10,001 participants · Start Apr 3, 1998 · Primary completion May 1, 2007
Drug: Atorvastatin · For: Cardiovascular Diseases
Fudan UniversityAcademic, hospital or other
NCT03418974 · 10,000 participants · Start Nov 1, 2017 · Primary completion Dec 31, 2021
Drug: Pitavastatin; Atorvastatin and 1 more · For: Dyslipidemias
Sites: Beijing, China; Shanghai, China
- A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)Pivotal-lookingActive, not recruiting
Monash UniversityAcademic, hospital or other
NCT02099123 · 9,971 participants · Start Jul 2015 · Primary completion Dec 2025
Drug: Atorvastatin; Placebo (for Atorvastatin) · For: Independent Living; Disability Free Survival; Elderly and 1 more
Sites: Hobart, Australia; Melbourne, Australia; Adelaide, Australia · 6 sites in all
- A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target LevelsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00327691 · 8,600 participants · Start Apr 1998
Drug: Atorvastatin · For: Cardiovascular Disease; Cerebrovascular Accident; Coronary Heart Disease
Sites: Alabaster, Alabama; Birmingham, Alabama; Hoover, Alabama · 314 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue14,464
- drug ineffective13,345
- nausea12,922
- diarrhoea11,692
- dyspnoea11,668
- type 2 diabetes mellitus11,263
- pain10,427
- headache10,307
- dizziness10,189
- myalgia10,017
- asthenia9,153
- arthralgia8,830
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5,709 |
| 2005 | 7,580 |
| 2006 | 8,146 |
| 2007 | 6,977 |
| 2008 | 6,528 |
| 2009 | 7,351 |
| 2010 | 14,619 |
| 2011 | 11,544 |
| 2012 | 13,815 |
| 2013 | 10,592 |
| 2014 | 15,345 |
| 2015 | 15,342 |
| 2016 | 14,718 |
| 2017 | 12,745 |
| 2018 | 12,859 |
| 2019 | 13,144 |
| 2020 | 12,183 |
| 2021 | 10,534 |
| 2022 | 10,498 |
| 2023 | 9,454 |
| 2024 | 9,967 |
| 2025 | 10,971 |
| 2026 | 8,029 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lipitor (Atorvastatin Calcium)
2024 spending
$26.8M
Beneficiaries
6,920
23,269 claims
Per beneficiary
$3,873
$15.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $73,147,637 |
| 2021 | $39,227,775 |
| 2022 | $34,489,246 |
| 2023 | $32,942,705 |
| 2024 | $26,798,187 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis.
Jaam M, Al-Naimi HN, Haddad MM, et al. · J Comp Eff Res 2023 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.
Lee JE, Yu SH, Kim SR, et al. · Diabetes Metab J 2024 · Randomized Controlled Trial, Multicenter Study
- A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases.
Li W, Wang D, Lin C, et al. · Cardiovasc Ther 2025 · Meta-Analysis, Systematic Review
- Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis.
Sayehmiri K, Shohani M, Qavam S, et al. · Life Sci 2025 · Systematic Review, Meta-Analysis
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, et al. · N Engl J Med 2005 · Clinical Trial, Multicenter Study
- Cerivastatin for lowering lipids.
Adams SP, Tiellet N, Alaeiilkhchi N, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.